Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.99 USD | +9.15% | -1.85% | +75.38% |
May. 09 | Larimar Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 09 | Zafgen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.38% | 467M | |
+5.01% | 111B | |
+12.34% | 105B | |
-12.79% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.96% | 16.96B | |
+4.61% | 13.7B | |
+36.47% | 12.45B |
- Stock Market
- Equities
- LRMR Stock
- News Larimar Therapeutics, Inc.
- Transcript : Zafgen, Inc., Q2 2018 Earnings Call, Aug 07, 2018